Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to 0.76%.

  • Barinthus Biotherapeutics' Return on Capital Employed fell 3800.0% to 0.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.76%, marking a year-over-year decrease of 3800.0%. This contributed to the annual value of 0.4% for FY2024, which is 300.0% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Return on Capital Employed is 0.76%, which was down 3800.0% from 0.62% recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Return on Capital Employed peaked at 0.02% during Q3 2022, and registered a low of 0.76% during Q3 2025.
  • Its 5-year average for Return on Capital Employed is 0.29%, with a median of 0.27% in 2023.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first soared by 1700bps in 2022, then tumbled by -4200bps in 2023.
  • Barinthus Biotherapeutics' Return on Capital Employed (Quarter) stood at 0.18% in 2021, then soared by 91bps to 0.02% in 2022, then crashed by -2529bps to 0.4% in 2023, then dropped by -7bps to 0.43% in 2024, then plummeted by -77bps to 0.76% in 2025.
  • Its Return on Capital Employed stands at 0.76% for Q3 2025, versus 0.62% for Q2 2025 and 0.51% for Q1 2025.